• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists.

作者信息

Pearson Mackenzie J, Unger Roger H, Holland William L

机构信息

Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX.

Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX VA North Texas Health Care System, Dallas, TX.

出版信息

Diabetes Care. 2016 Jul;39(7):1075-7. doi: 10.2337/dci15-0033.

DOI:10.2337/dci15-0033
PMID:27330122
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5876017/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6389/5876017/eb2c2a1a291b/dci150033f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6389/5876017/eb2c2a1a291b/dci150033f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6389/5876017/eb2c2a1a291b/dci150033f1.jpg

相似文献

1
Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists.胰高血糖素受体拮抗剂的临床试验、成功与困境
Diabetes Care. 2016 Jul;39(7):1075-7. doi: 10.2337/dci15-0033.
2
Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).小分子胰高血糖素受体拮抗剂：专利综述（2011 - 2014年）
Expert Opin Ther Pat. 2015 Jul;25(7):819-30. doi: 10.1517/13543776.2015.1032250. Epub 2015 Mar 31.
3
Recent progress in the development of small-molecule glucagon receptor antagonists.小分子胰高血糖素受体拮抗剂研发的最新进展
Bioorg Med Chem Lett. 2015 Oct 1;25(19):4057-64. doi: 10.1016/j.bmcl.2015.07.092. Epub 2015 Aug 1.
4
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.处于糖尿病I期和II期临床试验的研究性胰高血糖素受体拮抗剂。
Expert Opin Investig Drugs. 2017 Dec;26(12):1373-1389. doi: 10.1080/13543784.2017.1395020. Epub 2017 Oct 26.
5
Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.肽基和非肽基胰高血糖素受体拮抗剂在体内的肝胰高血糖素受体结合及降糖作用
Eur J Pharmacol. 2004 Oct 6;501(1-3):225-34. doi: 10.1016/j.ejphar.2004.08.023.
6
Advances in non-peptide glucagon receptor antagonists.非肽类胰高血糖素受体拮抗剂的进展
Curr Pharm Des. 1999 Sep;5(9):683-691.
7
Glucagon receptor antagonists might stimulate β-cell expansion.胰高血糖素受体拮抗剂可能会刺激β细胞增殖。
Nat Rev Endocrinol. 2022 Nov;18(11):659-660. doi: 10.1038/s41574-022-00735-x.
8
Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.发现呋喃-2-碳酰肼作为口服活性胰高血糖素受体拮抗剂。
Bioorg Med Chem Lett. 2014 Sep 1;24(17):4266-70. doi: 10.1016/j.bmcl.2014.07.025. Epub 2014 Jul 24.
9
Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.对葡萄糖依赖性促胰岛素多肽受体具有更高选择性的新型胰高血糖素受体拮抗剂。
J Med Chem. 2008 Sep 11;51(17):5387-96. doi: 10.1021/jm7015599. Epub 2008 Aug 16.
10
Discovery of potent, orally active benzimidazole glucagon receptor antagonists.强效口服活性苯并咪唑类胰高血糖素受体拮抗剂的发现。
Bioorg Med Chem Lett. 2008 Jul 1;18(13):3701-5. doi: 10.1016/j.bmcl.2008.05.072. Epub 2008 May 22.

引用本文的文献

1
Type 2 diabetes mellitus - conventional therapies and future perspectives in innovative treatment.2型糖尿病——传统疗法与创新治疗的未来展望
Biochem Biophys Rep. 2025 May 2;42:102037. doi: 10.1016/j.bbrep.2025.102037. eCollection 2025 Jun.
2
SEL1L-HRD1 ER-Associated Degradation Facilitates Prohormone Convertase 2 Maturation and Glucagon Production in Islet α Cells.SEL1L-HRD1内质网相关降解促进胰岛α细胞中激素原转化酶2的成熟和胰高血糖素的产生。
bioRxiv. 2025 Mar 20:2025.03.20.644437. doi: 10.1101/2025.03.20.644437.
3
Cardiac neurons expressing a glucagon-like receptor mediate cardiac arrhythmia induced by high-fat diet in .

本文引用的文献

1
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.胰高血糖素受体拮抗剂 LY2409021 治疗 2 型糖尿病患者的疗效和安全性评估：12 周和 24 周的 2 期研究。
Diabetes Care. 2016 Jul;39(7):1241-9. doi: 10.2337/dc15-1643. Epub 2015 Dec 17.
2
Glucagon receptor antagonism induces increased cholesterol absorption.胰高血糖素受体拮抗作用会导致胆固醇吸收增加。
J Lipid Res. 2015 Nov;56(11):2183-95. doi: 10.1194/jlr.M060897. Epub 2015 Sep 15.
3
Recent progress in the development of small-molecule glucagon receptor antagonists.
表达胰高血糖素样受体的心脏神经元介导高脂饮食诱导的心律失常。
bioRxiv. 2025 Mar 12:2023.12.13.571403. doi: 10.1101/2023.12.13.571403.
4
Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes.不同肥胖症和 2 型糖尿病小鼠模型中胰高血糖素代谢作用的可变性。
Mol Metab. 2024 Dec;90:102064. doi: 10.1016/j.molmet.2024.102064. Epub 2024 Nov 12.
5
An orally available compound suppresses glucagon hypersecretion and normalizes hyperglycemia in type 1 diabetes.一种口服化合物可抑制胰高血糖素分泌过多，并使 1 型糖尿病的高血糖恢复正常。
JCI Insight. 2024 Jan 23;9(2):e172626. doi: 10.1172/jci.insight.172626.
6
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges.用于代谢性疾病的多激动剂药物疗法：希望与新挑战
Drugs. 2024 Feb;84(2):127-148. doi: 10.1007/s40265-023-01982-6. Epub 2023 Dec 21.
7
High Doses of Exogenous Glucagon Stimulate Insulin Secretion and Reduce Insulin Clearance in Healthy Humans.高剂量外源性胰高血糖素可刺激健康人体胰岛素分泌并降低胰岛素清除率。
Diabetes. 2024 Mar 1;73(3):412-425. doi: 10.2337/db23-0201.
8
Glucagon and Its Receptors in the Mammalian Heart.哺乳动物心脏中的胰高血糖素及其受体。
Int J Mol Sci. 2023 Aug 15;24(16):12829. doi: 10.3390/ijms241612829.
9
Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production.糖尿病中的高胰高血糖素血症：氨基酸代谢改变触发 mTORC1 激活，进而驱动胰高血糖素的产生。
Diabetologia. 2023 Oct;66(10):1925-1942. doi: 10.1007/s00125-023-05967-8. Epub 2023 Jul 22.
10
Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes.1 型糖尿病中用于β细胞保护的新型抗糖尿病药物。
Cells. 2023 May 25;12(11):1472. doi: 10.3390/cells12111472.
小分子胰高血糖素受体拮抗剂研发的最新进展
Bioorg Med Chem Lett. 2015 Oct 1;25(19):4057-64. doi: 10.1016/j.bmcl.2015.07.092. Epub 2015 Aug 1.
4
Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass.胰高血糖素将肝氨基酸分解代谢与 mTOR 依赖性α细胞质量调控偶联。
Cell Rep. 2015 Jul 21;12(3):495-510. doi: 10.1016/j.celrep.2015.06.034. Epub 2015 Jul 9.
5
Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway.胰高血糖素受体抗体通过破坏一种新的致糖尿病途径，在无胰岛素的情况下完全抑制1型糖尿病表型。
Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2503-8. doi: 10.1073/pnas.1424934112. Epub 2015 Feb 9.
6
Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.短期给予胰高血糖素受体拮抗剂 LY2409021 可降低健康人和 2 型糖尿病患者的血糖。
Diabetes Obes Metab. 2015 Apr;17(4):414-22. doi: 10.1111/dom.12446. Epub 2015 Mar 2.
7
Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.成纤维细胞生长因子 21（FGF21）和胰高血糖素样肽 1 有助于缺乏胰高血糖素受体的小鼠抵抗糖尿病。
Diabetes. 2014 Jan;63(1):101-10. doi: 10.2337/db13-0710. Epub 2013 Sep 23.
8
Metabolic manifestations of insulin deficiency do not occur without glucagon action.胰岛素缺乏引起的代谢异常的表现，若无胰高血糖素作用也不会发生。
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14972-6. doi: 10.1073/pnas.1205983109. Epub 2012 Aug 13.
9
Brain glucose sensing and neural regulation of insulin and glucagon secretion.脑葡萄糖感应与胰岛素和胰高血糖素分泌的神经调节。
Diabetes Obes Metab. 2011 Oct;13 Suppl 1:82-8. doi: 10.1111/j.1463-1326.2011.01453.x.
10
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis.在小鼠中双重消除胰高血糖素和 GLP-1 受体揭示了肠促胰岛素轴的可塑性。
J Clin Invest. 2011 May;121(5):1917-29. doi: 10.1172/JCI43615. Epub 2011 Apr 11.